| 6.43 -0.02 (-0.31%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.73 | 1-year : | 9.03 |
| Resists | First : | 6.62 | Second : | 7.73 |
| Pivot price | 5.9  |
|||
| Supports | First : | 5.72 | Second : | 5.17 |
| MAs | MA(5) : | 6.28 |
MA(20) : | 5.81 |
| MA(100) : | 6.24 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 82.6 |
D(3) : | 73.6 |
| RSI | RSI(14): 60.5 |
|||
| 52-week | High : | 8.6 | Low : | 4.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AURA ] has closed below upper band by 21.2%. Bollinger Bands are 112.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.51 - 6.55 | 6.55 - 6.58 |
| Low: | 6.29 - 6.33 | 6.33 - 6.37 |
| Close: | 6.37 - 6.44 | 6.44 - 6.5 |
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Mon, 24 Nov 2025
Aura Biosciences (NASDAQ: AURA) CEO Fireside Chat at Evercore Healthcare Conf. 2025 - Stock Titan
Mon, 24 Nov 2025
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewswire
Mon, 17 Nov 2025
Top Executive Makes Bold Move with Aura Biosciences Stock Sale! - TipRanks
Sat, 15 Nov 2025
Aura Biosciences: Bringing Not-Quite-Viruses Closer To Fruition In Cancer (NASDAQ:AURA) - Seeking Alpha
Fri, 14 Nov 2025
Buy Rating on Aura Biosciences Inc. Driven by Promising Pipeline and Strategic Expansion in Ocular Oncology - TipRanks
Thu, 13 Nov 2025
Aura Biosciences Reports Q3 2025 Financial Results - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 84.5 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 3,140 (K) |
| EPS | -1.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.9 % |
| Return on Equity (ttm) | -64.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -3.37 |
| PEG Ratio | 0 |
| Price to Book value | 2.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|